Literature DB >> 33658026

Effects of mineral complex material treatment on 2,4- dinitrochlorobenzene-induced atopic dermatitis like-skin lesions in mice model.

Johny Bajgai1, Jing Xingyu1,2, Ailyn Fadriquela1,3, Rahima Begum1, Dong Heui Kim1, Cheol-Su Kim1, Soo-Ki Kim4, Kyu-Jae Lee5,6.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic allergic inflammatory skin disease characterized by complex pathogenesis including skin barrier dysfunction, immune-redox disturbances, and pruritus. Prolonged topical treatment with medications such as corticosteroids, calcineurin inhibitors, and T-cell inhibitors may have some potential side-effects. To this end, many researchers have explored numerous alternative therapies using natural products and mineral compounds with antioxidant or immunomodulatory effects to minimize toxicity and adverse-effects. In the current study, we investigated the effects of mineral complex material (MCM) treatment on 2, 4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in SKH-1 hairless mice.
METHODS: Animals were divided into four groups; normal control (NC), negative control treated with DNCB only (DNCB only), positive control treated with DNCB and tacrolimus ointment (PC) and experimental group treated with DNCB and MCM patch (MCM). Skin inflammation and lesion severity were investigated through analyses of skin parameters (barrier score and strength, moisture and trans-epidermal water loss level), histopathology, immunoglobulin E, and cytokines. In addition, reactive oxygen species (ROS), nitric oxide (NO), glutathione peroxidase (GPx), and catalase (CAT) levels were measured in both serum and skin lysate.
RESULTS: Our results demonstrates that MCM patch improved the progression of AD-like skin lesions by significantly increasing skin barrier strength and decreasing trans-epidermal water loss. Additionally, dermal administration of MCM patch significantly reduced epidermal thickness, ROS, and NO levels in skin lysate. Furthermore, we found that MCM suppressed the levels of AD-involved (Th1 and Th2) cytokines such as IL-2, IFN-γ, and IL-4 in blood. In addition, the levels of other Th1, and Th2 and inflammatory cytokines such as IL-1β, TNF-α, IL-6, IL-12(p70) and IL-10 were found lowest in the MCM group than in the DNCB only and PC groups. Moreover, we found total serum IgE level significantly increased after DNCB treatment, but decreased in the PC and MCM groups.
CONCLUSION: Taken together, our findings suggest that MCM application may have beneficial effects either systemic or regional on DNCB-induced AD lesional skin via regulation of the skin barrier function and immune-redox response.

Entities:  

Keywords:  Atopic dermatitis; Dinitrochlorobenzene; Immune redox; Inflammatory disease; Mineral complex material patch

Year:  2021        PMID: 33658026     DOI: 10.1186/s12906-021-03259-5

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  37 in total

Review 1.  Epidemiology of atopic dermatitis.

Authors:  H C Williams
Journal:  Clin Exp Dermatol       Date:  2000-10       Impact factor: 3.470

Review 2.  A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis.

Authors:  M Grewe; C A Bruijnzeel-Koomen; E Schöpf; T Thepen; A G Langeveld-Wildschut; T Ruzicka; J Krutmann
Journal:  Immunol Today       Date:  1998-08

3.  Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice.

Authors:  Yujung Jung; Jin-Chul Kim; No-June Park; Sim-Kyu Bong; Sullim Lee; Hyun Jegal; Li Tai Jin; Sang Moo Kim; Yong Kee Kim; Su-Nam Kim
Journal:  Biochem Biophys Res Commun       Date:  2018-01-17       Impact factor: 3.575

Review 4.  Pathogenesis of atopic dermatitis.

Authors:  D Y Leung
Journal:  J Allergy Clin Immunol       Date:  1999-09       Impact factor: 10.793

Review 5.  An Update on the Pathophysiology of Atopic Dermatitis.

Authors:  Kunal Malik; Kerry D Heitmiller; Tali Czarnowicki
Journal:  Dermatol Clin       Date:  2017-05-06       Impact factor: 3.478

6.  Th2 Cytokines and Atopic Dermatitis.

Authors:  Eric B Brandt; Umasundari Sivaprasad
Journal:  J Clin Cell Immunol       Date:  2011-08-10

7.  Role of reactive oxygen species and antioxidants in atopic dermatitis.

Authors:  N Sivaranjani; S Venkata Rao; G Rajeev
Journal:  J Clin Diagn Res       Date:  2013-12-15

Review 8.  Epidermal barrier dysfunction in atopic dermatitis.

Authors:  Michael J Cork; Simon G Danby; Yiannis Vasilopoulos; Jonathan Hadgraft; Majella E Lane; Manar Moustafa; Richard H Guy; Alice L Macgowan; Rachid Tazi-Ahnini; Simon J Ward
Journal:  J Invest Dermatol       Date:  2009-06-04       Impact factor: 8.551

Review 9.  New insights into atopic dermatitis.

Authors:  Donald Y M Leung; Mark Boguniewicz; Michael D Howell; Ichiro Nomura; Qutayba A Hamid
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 10.  Atopic dermatitis: recent trends in pathogenesis and therapy.

Authors:  K D Cooper
Journal:  J Invest Dermatol       Date:  1994-01       Impact factor: 8.551

View more
  2 in total

1.  Ta-Xi-San Suppresses Atopic Dermatitis Involved in Multitarget Mechanism Using Experimental and Network Pharmacology Analysis.

Authors:  Wenbing Zhi; Chun Li; Hong Zhang; Yiding Zhao; Shiyu Zong; Qiqi Liu; Jie Zhou; Chunliu Wang; Tingting Sun; Yang Liu; Ye Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-18       Impact factor: 2.650

Review 2.  The role of autophagy in hepatic fibrosis.

Authors:  Mei Sun; Li Tan; Min Hu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.